Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Non-Current Deferred Tax Liability (2017 - 2025)

Avalo Therapeutics (AVTX) has disclosed Non-Current Deferred Tax Liability for 9 consecutive years, with $304000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deferred Tax Liability rose 97.4% year-over-year to $304000.0, compared with a TTM value of $304000.0 through Sep 2025, up 97.4%, and an annual FY2024 reading of $270000.0, up 74.19% over the prior year.
  • Non-Current Deferred Tax Liability was $304000.0 for Q3 2025 at Avalo Therapeutics, up from $293000.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $304000.0 in Q3 2025 and bottomed at $111000.0 in Q1 2021.
  • Average Non-Current Deferred Tax Liability over 5 years is $171157.9, with a median of $154000.0 recorded in 2024.
  • The sharpest move saw Non-Current Deferred Tax Liability fell 6.1% in 2024, then surged 97.4% in 2025.
  • Year by year, Non-Current Deferred Tax Liability stood at $113000.0 in 2021, then grew by 24.78% to $141000.0 in 2022, then increased by 9.93% to $155000.0 in 2023, then soared by 74.19% to $270000.0 in 2024, then rose by 12.59% to $304000.0 in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for AVTX at $304000.0 in Q3 2025, $293000.0 in Q2 2025, and $278000.0 in Q1 2025.